BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

So really, the aim for us is to decrease neuropathic pain daily, for long term," says ... a software engineer, a clinical ...

Neuropathic pain is caused by disorders of, or damage to, the nervous system. The affected nerves can induce the sensation of pain in the brain. Neuropathic pain is often associated with the ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. CFTX-1554 is under development for the treatment of peripheral ...

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Central or peripheral neuropathic pain can be caused by a wide range of injuries ... Hutchinson Cory Toth MD is an Associate Professor in the Department of Clinical Neurosciences, a member of the ...

People with severe, treatment-resistant depression who received a nerve-stimulating therapy ... to the results of a national, multicenter clinical trial led by Washington University School of ...

The efficacy of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy has been established in several controlled clinical trials. [17,18,19] These trials ...

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...

Neuropathic ... the pain and temperature sensory fibers as they cross the midline. Their loss in the upper extremity, with intact position sense and motor function, is often the first clinical ...